UmanDiagnostics has signed a new licensing and supply agreement with global giant Siemens.
“Siemens is a world leader in our industry, so this is an extremely important agreement for us,” says Niklas Norgren, CEO of UmanDiagnostics.
Acquired by Quanterix
This summer UmanDiagnostics was purchased by major US life science company Quanterix for $22,5 million, and later went on to win both the Technology Award of the Year and Spin-Off Company of the Year at Umeågalan 2019.
A licensing and supply agreement
Now UmanDiagnostics, with the help of Quanterix, has signed a licensing and supply agreement with Siemens Healthineers in which Siemens has acquired access to UmanDiagnostics’ antibodies.
“Siemens’ access to our antibodies enables them to develop blood-based clinical trials for commercialisation via their global analysis platforms,” says Niklas Norgren. “This agreement is extremely important to us. It will enable a far broader use of our antibodies and provides an opportunity to help millions of patients with multiple sclerosis, Alzheimer’s disease, Parkinson’s disease and ALS.”
“A sharp increase in recognition for our biomarker”
“Our collaboration with Quanterix – and now this agreement with Siemens – will mean a sharp increase in recognition for our biomarker as well as an increase in sales of our other products. The outlook for the years ahead is very promising and we are convinced our new agreements will benefit Umeå,” concludes Niklas Norgren.
Photo of Eva Söderström and Niklas Norgren, UmanDiagnostics. Photographer: Carolina Hawranek
